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Summary
Background Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric 
convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and 
safer alternative. This trial compared the efficacy and safety of phenytoin and levetiracetam for second-line 
management of paediatric convulsive status epilepticus.
Methods This open-label, randomised clinical trial was undertaken at 30 UK emergency departments at secondary 
and tertiary care centres. Participants aged 6 months to under 18 years, with convulsive status epilepticus requiring 
second-line treatment, were randomly assigned (1:1) using a computer-generated randomisation schedule to receive 
levetiracetam (40 mg/kg over 5 min) or phenytoin (20 mg/kg over at least 20 min), stratified by centre. The primary 
outcome was time from randomisation to cessation of convulsive status epilepticus, analysed in the modified 
intention-to-treat population (excluding those who did not require second-line treatment after randomisation and 
those who did not provide consent). This trial is registered with ISRCTN, number ISRCTN22567894.
Findings Between July 17, 2015, and April 7, 2018, 1432 patients were assessed for eligibility. After exclusion of ineligible 
patients, 404 patients were randomly assigned. After exclusion of those who did not require second-line treatment and 
those who did not consent, 286 randomised participants were treated and had available data: 152 allocated to 
levetiracetam, and 134 to phenytoin. Convulsive status epilepticus was terminated in 106 (70%) children in the 
levetiracetam group and in 86 (64%) in the phenytoin group. Median time from randomisation to cessation of 
convulsive status epilepticus was 35 min (IQR 20 to not assessable) in the levetiracetam group and 45 min 
(24 to not assessable) in the phenytoin group (hazard ratio 1·20, 95% CI 0·91–1·60; p=0·20). One participant who 
received levetiracetam followed by phenytoin died as a result of catastrophic cerebral oedema unrelated to either 
treatment. One participant who received phenytoin had serious adverse reactions related to study treatment 
(hypotension considered to be immediately life-threatening [a serious adverse reaction] and increased focal seizures 
and decreased consciousness considered to be medically significant [a suspected unexpected serious adverse reaction]). 
Interpretation Although levetiracetam was not significantly superior to phenytoin, the results, together with previously 
reported safety profiles and comparative ease of administration of levetiracetam, suggest it could be an appropriate 
alternative to phenytoin as the first-choice, second-line anticonvulsant in the treatment of paediatric convulsive status 
epilepticus.
Funding National Institute for Health Research Health Technology Assessment programme.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Convulsive status epilepticus is the most common 
paediatric neurological emergency worldwide.1 It has an 
annual incidence of 20 per 100 000 children, and is the 
second most common reason for unplanned admissions 
to paediatric intensive care units (PICUs) in the UK.2 
Mortality is low, but morbidity, including neurodisability, 
learning difficulties, and de-novo and drug-resistant 
epilepsy, could be as high as 22%.3–6 The longer the 
duration of convulsive status epilepticus, the more difficult 
it is to terminate, and the greater the risk of morbidity.1,5,6
Convulsive status epilepticus is treated using an 
algorithm recommended by Advanced Paediatric Life 
Support (APLS), which incorporates 10 min intervals 
between treatments.7 Second-line treatment is given 
when convulsive status epilepticus persists either after 
two doses of benzodiazepine or the child’s personalised 
emergency (rescue) treatment. Failure of second-line 
treatment is followed by anaesthesia via rapid sequence 
induction (RSI).7 Randomised clinical trial evidence 
supports the use of benzodiazepines as first-line treat-
ment.8 However, no high-quality randomised clinical 
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trial evidence exists to support any second-line 
treatment.9
The currently recommended second-line treatment for 
convulsive status epilepticus is intravenous phenytoin in 
the UK and Europe (fosphenytoin in the USA), based on 
predominantly non-randomised clinical trial data; reported 
cessation rates vary widely between 50% and 96%.10,11 Safety 
concerns are widely reported, particularly cardiovascular 
disturbance (hypotension and fatal arrhythmias) and 
Stevens-Johnson syndrome.12–14 Levetiracetam has been 
reported to be effective and well tolerated in the 
management of serial seizures and convulsive status 
epilepticus, also based on predominantly retrospective and 
observational trial data, with reported rates of convulsive 
status epilepticus cessation between 44% and 94%.9,11,15–17 
Adverse reactions with levetiracetam seem to be less 
frequent and less severe than with phenytoin.18 
Levetiracetam is admin istered more rapidly (5–10 min) 
than phenytoin (a minimum of 20 min), suggesting that 
more rapid termination of convulsive status epilepticus 
could be possible with levetiracetam. However, findings of 
existing studies of second-line treatments cannot be 
generalised because of methodological issues, including 
small sample sizes and heterogeneity of primary outcomes. 
Management of convulsive status epilepticus was therefore 
identified as one of five priority areas for research by the 
UK National Institute for Health and Care Excellence in its 
epilepsy guideline published in 2012.19
The Emergency treatment with Levetiracetam or 
Phenytoin in convulsive Status Epilepticus in children 
(EcLiPSE) trial aimed to determine whether intravenous 
levetiracetam or intravenous phenytoin is the more 
effective and safer second-line anticonvulsant for 
emergency management of paediatric convulsive status 
epilepticus.
Methods
Study design
We did an open-label randomised clinical trial at 30 UK 
emergency departments, all of which are members of 
Paediatric Emergency Research in the United Kingdom 
& Ireland (PERUKI).20 These emergency departments 
were secondary care (district general hospitals) and 
tertiary care centres.
Ethical approval was gained from the National Research 
Ethics Service, Liverpool Central, on March 3, 2016; all 
participating centres were granted permission from 
the UK National Health Service before commencing 
recruitment.
The trial protocol has been published21 and is also 
available in full online.
Participants
Children of either sex, aged 6 months to under 18 years, 
presenting with convulsive status epilepticus (generalised 
tonic-clonic, generalised clonic, or focal clonic seizure) 
Research in context
Evidence before this study
We searched Embase and MEDLINE with no language or date 
restrictions on Jan 1, 2013, using the search strategy of the 
Cochrane Epilepsy Group publications that described use of 
intravenous levetiracetam and phenytoin as a first-line or second-
line antiepileptic drug or anticonvulsant in the management of 
status epilepticus, convulsive status epilepticus, and serial seizures 
in children and adults. There are few randomised clinical trial data 
for the second-line anticonvulsant treatment of paediatric 
convulsive status epilepticus. Most published evidence for both 
phenytoin (the current recommended first-choice, second-line 
anticonvulsant outside the USA) and levetiracetam is anecdotal, 
retrospective,or both, and predominantly based on studies in 
adults. Observational data suggest that levetiracetam is more 
effective than phenytoin. Two small randomised clinical trials 
undertaken predominantly in adults and a recent paediatric 
randomised clinical trial, using a range of methodologies and 
outcomes, found no significant difference between phenytoin 
and levetiracetam in the rate of cessation of convulsive status 
epilepticus or recurrence of convulsive status epilepticus 
within 24 h.
Added value of this study
This is an adequately powered randomised clinical trial that 
directly compares anticonvulsants for second-line treatment of 
paediatric convulsive status epilepticus in an emergency 
setting. It is also the first randomised clinical trial to compare 
the efficacy and safety of levetiracetam and phenytoin in this 
paediatric neurological emergency. We found no significant 
differences between the two anticonvulsants in any primary or 
secondary outcomes, including time to seizure cessation and 
need for additional anticonvulsants. The safety profile was 
similar between treatments, by contrast with existing 
observational evidence that phenytoin has a worse 
safety profile.
Implications of all the available evidence
Our results suggest that levetiracetam could be considered as 
an alternative treatment to phenytoin for second-line 
management of paediatric convulsive status epilepticus. 
Possible benefits of levetiracetam over phenytoin include its 
ease of preparation and administration, minimal interaction 
with antiepilepsy and other drugs, and easy conversion to oral 
maintenance therapy. Further randomised clinical trial and 
meta-analysis data could help to confirm our results and might 
lead to levetiracetam being the preferred second-line 
anticonvulsant in children with benzodiazepine-resistant 
convulsive status epilepticus.
For the trial protocol see 
https://www.journalslibrary.nihr.
ac.uk/programmes/
hta/12127134/#
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that required second-line treatment were eligible for 
inclusion. Patients were ineligible if they presented 
with absence, myoclonic, or non-convulsive status epi-
lepticus, or infantile spasms; were known or suspected 
to be pregnant; had a contraindication or allergy to 
levetiracetam or phenytoin; had established renal failure; 
had received a second-line anticonvulsant during the 
presenting episode of convulsive status epilepticus, 
before screening; or were known to have been previously 
enrolled in the EcLiPSE trial.
We used research without prior consent (also known as 
deferred consent) because of the time-crucial manage-
ment of convulsive status epilepticus, in accordance with 
regulatory requirements, research without prior consent 
guidance, and pretrial research.22–24 The process of 
research without prior consent in EcLiPSE was formally 
assessed and evaluated in a nested consent study. The 
primary objective was to assess how well the process of 
consent was conducted and understood by parents and 
legal representatives and the medical and nursing staff at 
each participating site. The nested consent study findings 
will be published separately.21 Parents, legal repre-
sentatives or guardians, and patients were approached 
once the patient’s clinical condition was stable (ideally 
within 24 h of randomisation and before discharge from 
hospital), at which point written informed consent was 
sought to continue data collection and use data already 
collected.21 When consent was not sought before 
discharge, participants or parents or legal guardians were 
contacted within 5 working days of randomisation by a 
member of the research team, and informed of their 
involvement and trial details. Participants were sent 
written information, a consent form, and a covering 
letter stating that they had 4 weeks from the date of the 
letter to confirm or decline participation. We used an opt-
out postal approach; the covering letter explained that the 
participant would be included in the trial if no response 
was received.
Randomisation and masking
Participants were randomly assigned (1:1) to receive 
levetiracetam or phenytoin using random variable block 
sizes of two and four. A computer-generated random-
isation schedule was produced by an independent 
statistician who had no further involvement in the study, 
stratified by centre. Sites were provided with randomisation 
packs, which were sequentially numbered, heavy duty, 
opaque, A4 cardboard envelopes with tamper-proof closure 
strips to be opened in ascending order. Each envelope 
contained the random treatment allocation and relevant 
case report form. Periodic checks ensured sites had the 
correct number of envelopes, that they were intact, and 
that the sequential numbering system was maintained.
Treating clinicians opened randomisation envelopes 
after confirmation of eligibility. This was undertaken 
after administration of the final first-line treatment to 
allow sufficient time to prepare and administer the 
allocated second-line treatment in accordance with the 
APLS algorithm.7 If convulsive status epilepticus stopped 
before administration of the allocated treatment, 
participants were excluded; however, these participants 
could be subsequently included if their seizure restarted 
and required a second-line treatment while in the 
emergency department. Emergency department team 
members were aware of the allocated drug, and the 
treating emergency clinician determined time of ces-
sation of convulsive status epilepticus based on clinical 
examination. 
Participants, parents, legal representatives and 
guardians, and clinicians were all informed of allocated 
treatments. The statistician was not masked to treatment 
allocation because the database containing the trial data 
included treatments received. Amendments to the 
analysis plan were considered and implemented by a 
masked statistician, which included masked collection 
and analysis of the data before database lock. Inclusion in 
the analysis sets was determined without reference to 
treatments received with independent determination by 
another statistician.
Procedures
Convulsive status epilepticus was managed according to 
the APLS algorithm, and both study treatments were 
given intravenously.7,21 Levetiracetam was administered 
over 5 min in a dose of 40 mg/kg (maximum dose 2·5 g); 
phenytoin was administered over a minimum of 20 min 
in a dose of 20 mg/kg (maximum dose 2 g and with a 
maximum infusion rate of 1 mg/kg per min). Clinicians 
treated subsequent ongoing convulsive status epilepticus 
according to the APLS algorithm.7
Data were recorded on a paper-based case report 
form by emergency clinicians during the convulsive 
status epilepticus, including times of randomisation, 
com mence ment and completion of infusions, and 
cessation of convulsive status epilepticus. These key data 
were collated and highlighted on the first page of the 
case report form to ensure data accuracy. Additional 
information included participant demographics, type 
of convulsive status epilepticus, site of trial treatment 
administration, need for additional anticonvulsants, 
RSI, and adverse events. After consent, information was 
collected on pre-existing epilepsy diagnosis, oral main-
tenance antiepilepsy drugs, neuro logical comorbidities, 
concomitant medications, aetiology of convulsive status 
epilepticus, patient location on admission and at 24 h, 
and further seizure activity within 24 h. Final follow-up 
was undertaken 14 days after enrolment by chart review 
(recording discharge, re admission, death, and organ 
failure), and a brief participant postal questionnaire 
(assessing current participant health, new medical 
problems, and new antiepilepsy drugs).
At each site initiation visit, training of the site’s 
medical and nursing staff included a simulated 
demonstration of the processes of screening, 
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randomisation, and assess ment of the endpoint to 
ensure a consistent understanding of the primary 
outcome measure.
Outcomes
The primary outcome was time from randomisation to 
cessation of all visible signs of convulsive activity, defined 
as cessation of all continuous rhythmic clonic activity, as 
judged by the treating clinician.
Secondary outcomes were need for further anti-
convulsants to manage the convulsive status epilepticus 
after administration of the trial treatment; need for RSI 
because of ongoing convulsive status epilepticus; need for 
admission to critical care (either a high-dependency unit or 
a PICU); and serious adverse reactions (including death, 
Stevens-Johnson syndrome, rash, airway complications, 
cardiovascular instability, extravasation injury, and extreme 
agitation, as well as those listed in the summary product 
characteristic of each treatment). 
All adverse events, including serious adverse events, 
and adverse reactions and their causes were assessed by 
the principal investigator at each participating site and 
within the context of each treatment’s summary of product 
characteristics.
Statistical analysis
The sample size was calculated on the basis of existing 
reported seizure cessation rates for phenytoin and 
levetiracetam.10,18 140 randomised and consented partici-
pants per group, with a total of 183 events (of convulsive 
status epilepticus cessation) were required for a 
0·05 level two-sided log-rank test for equality of survival 
curves to detect an increase in seizure cessation from 
60% to 75% (a constant hazard ratio [HR] of 0·661) at 
80% power. The sample size was increased to 
308 to allow for 10% loss to follow-up. The final sample 
size was 286 due to low attrition and completeness of 
primary outcome data.
The primary analysis was based on a modified 
intention-to-treat (mITT) principle. All randomised and 
consented participants who received a second-line 
treatment were included in the analysis according to 
their allocated treatment. Children who were randomised 
but whose convulsive status epilepticus stopped without 
requiring second-line treatment (and did not restart 
in the emergency department) were excluded. The 
safety analysis included the same participants, grouped 
according to actual treatment received. To avoid double-
counting, serious adverse events are reported separately 
from adverse events.
Statistical tests were two-sided at a 5% significance 
level; results are presented with 95% CIs. The primary 
outcome was analysed using the log-rank test and is 
presented as a Kaplan-Meier curve. All participants were 
followed up to cessation of convulsive status epilepticus, 
with censoring used in the event of RSI or death. If RSI 
was administered, time was censored at RSI plus 12 h 
(720 min); in patients who died before cessation of 
convulsive status epilepticus, time was censored at time 
of death plus 48 h (2880 min). Sensitivity analyses were 
done to test the robustness of results of the analysis 
approach taken including: Gray’s test,25 treating RSI as 
a competing risk, calculating time to cessation of 
convulsive status epilepticus from start of infusion 
instead of randomisation, and censoring participants at 
the time of an additional second-line treatment after no 
response to the allocated treatment.
Additional analysis using a Cox proportional hazards 
model adjusted for baseline characteristics of weight 
(<12 kg, 12–36 kg, or >36 kg), sex, and whether this was 
the child’s first seizure. Two covariates (site of infusion 
and additional anticonvulsants given in parallel) 
specified in the analysis plan were not included because 
they were measured after randomisation. Additionally, 
centre could not be included in the Cox model due to 
lack of convergence. Schoenfeld residual plots were 
used to check the assumption of proportionality. The 
binary secondary outcomes of need for further 
anticonvulsants, RSI, and admission to critical care 
192 allocated to phenytoin
150 received second-line treatment
42 did not require second-line treatment 
134 received phenytoin 
134 included in mITT analysis
16 excluded from analysis
5 consent incompletely documented
11 declined consent
212 allocated to levetiracetam 
161 received second-line treatment
51 did not require second-line treatment 
1432 assessed for eligibility 
404 randomly allocated
(envelope opened)
 
1028 excluded before randomisation
972 did not meet eligibility criteria
53 eligible but not randomly allocated* 
3 incomplete eligibility data
149 received 
levetiracetam 
152 included in mITT analysis 
9 excluded from analysis
1 consent incompletely documented 
8 declined consent
3 received phenytoin
Figure 1: Trial profile
mITT=modified intention-to-treat. *Reasons included no trial-trained doctor available, loss of or failure to achieve 
intravenous access, clinical judgment (eg, child too sick), and treatment given before random assignment.
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were analysed using the χ² test and presented with 
relative risks. Logistic regression models were fitted as 
additional analyses to the primary χ² tests, with 
adjustments as per the Cox proportional hazards model. 
No adjustment was made for multiplicity for the 
secondary outcomes. Baseline categorical data and 
adverse event data are summarised using numbers and 
percentages, and continuous data are summarised as 
medians and IQRs.
A post-hoc analysis was undertaken for the reasons 
underlying the further management of the presenting 
episode of convulsive status epilepticus, the assessment 
of which was done without knowledge of the allocated 
intervention
A detailed statistical analysis plan is available online. All 
analyses were done with SAS software, version 9.4. The 
trial was overseen by an independent data and safety 
monitoring committee (IDSMC), which made recom-
mendations to a trial steering committee (TSC). The 
majority of the TSC were independent and remained 
masked to accumulating data until the end of the trial. 
The IDSMC and TSC met at least annually and were 
consulted before the decision to stop recruitment due to 
low attrition and completeness of data. The Haybittle-
Peto approach was used by the IDSMC as a guide to 
consider stopping the trial within interim reports with 
99·9% CIs. This trial is registered with ISRCTN, number 
ISRCTN22567894.
Role of the funding source
The funder monitored trial progress and approved 
membership of the oversight committees (IDSMC and 
TSC). The funder had no role in trial design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all data in the trial and had final responsibility for the 
decision to submit for publication.
Results
Between July 17, 2015, and April 7, 2018, 1432 children 
presented to participating emergency departments with 
convulsive status epilepticus. After exclusion of 1028 in-
eligible patients, 404 were randomly assigned (212 to 
levetiracetam and 192 to phenytoin). However, 93 patients 
did not require second-line treatment and 25 did not 
provide consent. Therefore, 286 randomised participants 
were treated, of whom 19 declined consent and six had 
incompletely documented consent, leaving 152 (53%) 
allocated to levetiracetam and 134 (47%) allocated to 
phenytoin in the mITT analysis (figure 1). Written consent 
Levetiracetam 
(n=152)
Phenytoin 
(n=134)
Sex
Male 75 (49%) 72 (54%)
Female 77 (51%) 62 (46%)
Age
6 months to <2 years 65 (43%) 53 (40%)
2–11 years 81 (53%) 74 (55%)
12–17 years 6 (4%) 7 (5%)
Median (IQR), years 2·7 (1·3–5·9) 2·7 (1·6–5·6)
Range, years 0·6–16·1 0·6–17·9
Weight
<12 kg 52 (34%) 42 (31%)
12–36 kg 86 (57%) 80 (60%)
>36 kg 14 (9%) 12 (9%)
Median (IQR) 12·1 (10·0–19·0) 12·0 (10·0–18·0)
Range 7·5–70·0 6·0–66·0
Participant’s first seizure 69 (45%) 49 (37%)
Presenting seizure type
Generalised tonic-clonic 107 (70%) 105 (78%)
Generalised clonic 12 (8%) 7 (5%)
Focal clonic 33 (22%) 22 (16%)
Seizure cause*
Febrile convulsion 63 (41%) 58 (43%)
Seizure (pre-existing epilepsy) 46 (30%) 46 (34%)
First afebrile seizure 16 (11%) 12 (9%)
CNS infection 6 (4%) 7 (5%)
Intracranial vascular event 
(bleed or stroke)
2 (1%) 2 (1%)
Traumatic brain injury 0 0
Substance misuse 1 (<1%) 0
Indeterminate 10 (7%) 7 (5%)
Other 27 (18%) 26 (19%)
Maintenance antiepilepsy drugs at presentation*†
Levetiracetam 29 (19%) 26 (19%)
Sodium valproate 16 (11%) 19 (14%)
Carbamazepine 12 (8%) 10 (7%)
Clobazam 9 (6%) 9 (7%)
Topiramate 4 (3%) 8 (6%)
Phenytoin 0 1 (<1%)
Other 11 (7%) 18 (13%)
Data are n (%), median (IQR), or range. *Categories not mutually exclusive. 
†Includes participants with an established diagnosis of epilepsy who were reciving 
antiepilepsy drugs at the time of random allocation to treatment.
Table 1: Baseline demographic and seizure characteristics
Levetiracetam 
(n=152)
Phenytoin 
(n=134)
Total  
(n=286)
Patient given lower dose of trial treatment 8 (5%) 4 (3%) 12 (4%)
Patient given higher dose of trial treatment 2 (1%) 1 (<1%) 3 (1%)
Dose administration shorter than expected 0 1 (<1%) 1 (<1%)
Dose administration longer than expected 27 (18%) 34 (25%) 61 (21%)
Treatment prematurely discontinued 0 2 (1%) 2 (<1%)
Unauthorised route of administration (intraosseous) 6 (4%) 0 6 (2%)
Received initial second-line treatment other than that 
allocated
3 (2%) 0 3 (<1%)
Received further second-line treatment* 22 (14%) 13 (10%) 35 (12%)
*Includes those who subsequently received the alternative trial treatment or an additional dose of the allocated 
treatment, within 24 h.
Table 2: Trial adherence
For the statistical analysis plan 
see https://www.journalslibrary.
nihr.ac.uk/programmes/
hta/12127134/#
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was obtained in 250 (87%), and the remaining 36 (13%) 
were included via the opt-out pathway. Baseline character-
istics were similar between groups (table 1).
Convulsive status epilepticus was terminated by 
levetiracetam in 106 (70%) participants, and by phenytoin 
in 86 (64%) participants. Three patients allocated to the 
levetiracetam group received phenytoin (table 2). Median 
time from randomisation to start of infusion was 11 min 
(IQR 8–15) for levetiracetam and 12 min (8–17) for 
phenytoin. Infusion duration was longer than expected 
for 27 (18%) participants allocated to levetiracetam and 
34 (25%) allocated to phenytoin. Two participants in the 
phenytoin group discontinued treatment early because 
of loss of intravenous access during drug administration 
(table 2). 
Median time from randomisation to seizure cessation 
was 35 min (IQR 20 to not assessable) in the levetiracetam 
group and 45 min (IQR 24 to not assessable) in the 
phenytoin group (log-rank test p=0·20; figure 2). Event 
times were censored for 46 (30%) participants in the 
levetiracetam group and 48 (36%) in the phenytoin group 
who received RSI for any reason before seizure cessation. 
The unadjusted HR was 1·20 (95% CI 0·91–1·60; 
p=0·20) in favour of levetiracetam. The Schoenfeld 
residuals for the un adjusted model (p=0·72) indicated 
the independency of time and the validity of the 
proportionality assumption. The Schoenfeld residuals 
for the adjusted model indicated that the assumption of 
proportionality for weight was not met (p=0·05, p value 
range from 0·27 to 0·71 for other variables; appendix). 
The proportionality assumption within each weight 
subgroup (<12 kg, 12–36 kg, or >36 kg) was supported by 
the Schoenfeld residuals. Direction of treatment effect 
was consistent across subgroups, confidence intervals 
were wide, and results were not significant (appendix). 
The treatment effect was increased for children in the 
over 36 kg subgroup; however, numbers within this 
group are small and the treatment effect was not 
significant (appendix). Sensitivity analyses undertaken 
on the primary outcome confirmed the robustness of the 
results (appendix).
57 (38%) participants in the levetiracetam group and 
50 (37%) in the phenytoin group received additional 
anticonvulsants (relative risk [RR] 1·01 [95% CI 0·74–1·36]; 
p=0·97; table 3). Results were similar in a post-hoc analysis 
restricted to further management for the presenting 
episode of convulsive status epilepticus. 44 (29%) partici-
pants in the levetiracetam group and 47 (35%) in the 
phenytoin group were given an RSI due to ongoing 
convulsive status epilepticus (RR 0·83 [95% CI 0·59–1·16]; 
p=0·27; table 3). 97 (64%) participants in the levetiracetam 
group and 72 (54%) in the phenytoin group were admitted 
to critical care (RR 1·19 [95% CI 0·97–1·45]; p=0·08).
132 participants received levetiracetam only and 
130 received phenytoin only. The remaining 24 participants 
received both treatments sequentially; 17 received 
levetiracetam followed by phenytoin, and seven received 
phenytoin followed by levetiracetam. 
20 adverse events were reported in 16 participants 
receiving levetiracetam, 23 adverse events were reported in 
18 participants receiving phenytoin, and eight adverse 
events were reported in four participants receiving 
both treatments. Each individual adverse event had a 
prevalence of less than 10% (table 4). The most common 
adverse event was agitation, which occurred in 11 (8%) 
who received levetiracetam and in four (3%) who received 
phenytoin (table 4).
Only five serious adverse events were observed (three in 
two participants receiving phenytoin, one in a participant 
receiving levetiracetam, and one in a participant who 
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Figure 2: Kaplan-Meier curve for time to seizure cessation
See Online for appendix
Levetiracetam 
(n=152)
Phenytoin 
(n=134)
Relative risk 
(95% CI)
p value
Secondary outcomes
Need for further anticonvulsants* 57 (37·5%) 50 (37·3%) 1·01 (0·74–1·36) 0·97
Need for further anticonvulsants 
for the presenting convulsive 
status epilepticus†
24 (15·8%) 20 (14·9%) 1·06 (0·61–1·83) 0·84
Need for further anticonvulsants 
for a subsequent seizure (within 
24 h)†‡
14 (9·2%) 17 (12·7%) 0·72 (0·37–1·40) 0·33
RSI to terminate an ongoing seizure 44 (30·0%) 47 (35·1%) 0·83 (0·59–1·16) 0·27
Admission to critical care 97 (63·8%) 72 (53·7%) 1·19 (0·97–1·45) 0·08
Serious adverse reaction 0 2 (1%)§ ·· ··
14-day follow-up
Discharged from hospital 145 (95%) 130 (97%) ·· ··
Readmitted to hospital 12 (8%) 10 (7%) ·· ··
Patient died 1 (<1%) 1 (<1%) ·· ··
Organ failure 1 (<1%) 0 ·· ··
Data are n (%) or relative risk (95% CI). RSI=rapid sequence induction. *Includes all instances of further anticonvulsant 
being given in following 24 h, including for the presenting seizure, subsequent seizures, or for prophylaxis. †Post-hoc 
analysis; assessment conducted without knowledge of the allocated intervention. ‡Excludes nine participants with 
unavailable data. §Two events in one participant, one of which was a suspected unexpected serious adverse reaction.
Table 3: Secondary outcomes and 14-day follow-up
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received both interventions) Four of these resolved; the 
remaining serious adverse event occurred in a participant 
who died as a result of catastrophic cerebral oedema 
unrelated to either treat ment (this participant received 
levetiracetam followed by phenytoin). Two of the serious 
adverse events were assessed as being related to 
treatment. One was a case of hypotension considered to 
be immediately life-threatening, which was classed as a 
serious adverse reaction, and the other was a case of 
increased focal seizures and decreased consciousness 
considered to be medically significant, which was classed 
as a suspected unexpected serious adverse reaction. Both 
occurred in the same participant, who was allocated to, 
and received phenytoin. The remaining serious adverse 
event occurred in a levetiracetam-treated participant who 
had a cardiorespiratory arrest due to an obstructed 
endotracheal tube, which was considered unrelated to 
treatment.
Discussion
In this open-label, multicentre trial, we did not detect 
a significant difference between phenytoin and 
levetiracetam in the second-line treatment of paediatric 
convulsive status epilepticus for any outcome, including 
time to seizure cessation. To our knowledge, this trial is 
the largest randomised clinical trial to date to compare 
levetiracetam with phenytoin for treatment of paediatric 
convulsive status epilepticus that was unresponsive to 
first-line treatment.
Convulsive status epilepticus cessation rates for 
levetiracetam (70%) and phenytoin (64%) in our trial were 
broadly similar to those previously reported in obser-
vational and retrospective studies in adult patients.10,16 
Cessation rates as high as 85–95% have been reported, but 
these studies have significant heterogeneity in design 
and outcomes.11,26 One randomised clinical trial undertaken 
in adults with convulsive status epilepticus compared the 
efficacy of intravenous phenytoin (20 mg/kg), valproate 
(30 mg/kg), and levetiracetam (25 mg/kg) in 150 patients 
unresponsive to intravenous lorazepam.17 Convulsive 
status epilepticus stopped in 34 (68%) patients treated with 
phenytoin, 34 (68%) treated with valproate, and 39 (78%) 
treated with levetiracetam (p=0·44). A recent paediatric 
randomised clinical trial evaluated 100 children aged 
3–12 years receiving levetiracetam (30 mg/kg) or phenytoin 
(20 mg/kg) if their convulsive status epilepticus continued 
after one dose of intravenous diazepam.11 Efficacy was high 
and almost identical in both groups. A lower diastolic 
blood pressure was recorded in phenytoin-treated patients. 
However, it is difficult to translate these findings to clinical 
practice because of the trial’s design, including many 
exclusion criteria and the primary outcome of absence of 
seizure activity within 24 h, which is not a clinically 
practical outcome.11 In UK practice, management of 
paediatric convulsive status epilepticus follows the APLS 
algorithm, which is applicable to the vast majority of 
children presenting to emergency departments.7 Our study 
design therefore used eligibility criteria that were as 
inclusive as possible, and followed a treatment pathway 
that reflected clinical practice.
We did not detect a significant difference between 
levetiracetam and phenytoin in time to cessation of 
convulsive status epilepticus. We used a superiority design 
for three reasons: reported convulsive status epilepticus 
cessation rates for each drug suggested that levetiracetam 
would be more effective than phenytoin; no randomised 
clinical trial data comparing the efficacy of either treatment 
to placebo were available; and levetiracetam has a shorter 
infusion time (5 min vs at least 20 min for phenytoin). We 
selected time from randomisation and instructed sites to 
undertake randomisation at the latest possible point that 
would allow reconstitution of the allocated treatment to 
provide scientific and clinical rigour. Because the median 
time to commencement of infusion exceeded 10 min in 
each group, we also undertook a sensitivity analysis using 
time to cessation from commencement of infusion, which 
supported the findings of our primary analysis.
Progression to RSI in convulsive status epilepticus 
can be required for one or a combination of reasons, 
including continuing convulsive status epilepticus, 
respiratory depression, clinical deterioration, or to 
stabilise the patient for transfer or to safely undertake 
investigations. However, RSI abolishes visible convulsive 
status epilepticus activity, and might therefore prevent 
assessment of seizure cessation directly related to trial 
treatment. Participants were therefore censored if they 
progressed to RSI, but the censoring time was increased 
Levetiracetam 
(n=132)
Phenytoin 
(n=130)
Both drugs  
(n=24)
Total  
(n=286)
Events Patients Events Patients Events Patients Events Patients
Any adverse event 20 16 (12%) 23 18 (14%) 8 4 (17%) 51 38 (13%)
Agitation 11 11 (8%) 4 4 (3%) 0 0 15 15 (5%)
Hypotension 2 2 (2%) 3 3 (2%) 1 1 (4%) 6 6 (2%)
Catheter site related 1 1 (<1%) 1 1 (<1%) 3 2 (8%) 5 4 (1%)
Extravasation 0 0 4 4 (3%) 1 1 (4%) 5 5 (2%)
Tachycardia 1 1 (<1%) 3 3 (2%) 1 1 (4%) 5 5 (2%)
Rash 2 2 (2%) 1 1 (<1%) 0 0 3 3 (1%)
Hypertension 0 0 2 2 (2%) 0 0 2 2 (<1%)
Reaction to ceftriaxone 0 0 0 0 1 1 (4%) 1 1 (<1%)
Confusion 1 1 (<1%) 0 0 0 0 1 1 (<1%)
Decreased 
consciousness
0 0 1 1 (<1%) 0 0 1 1 (<1%)
Hallucination 1 1 (<1%) 0 0 0 0 1 1 (<1%)
Infusion site erythema 0 0 1 1 (<1%) 0 0 1 1 (<1%)
Mechanical ventilation 
complication
0 0 1 1 (<1%) 0 0 1 1 (<1%)
Pallor 0 0 1 1 (<1%) 0 0 1 1 (<1%)
Stridor 0 0 0 0 1 1 (4%) 1 1 (<1%)
Vomiting 0 0 1 1 (<1%) 0 0 1 1 (<1%)
Wheezing 1 1 (<1%) 0 0 0 0 1 1 (<1%)
Table 4: Adverse events
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to allow for this to be a negative and potentially 
informative outcome. Increasing censoring time might 
have artificially inflated the time to cessation of convulsive 
status epilepticus. However, sensitivity analyses in which 
patients were censored at the time of RSI (and in which 
RSI was defined as a competing risk) did not change 
our findings.
Observed safety profiles were similar between treatment 
groups. Because of their relative infrequency in relation to 
the trial population size, together with good clinical 
management in participating sites, low rates of serious 
adverse events or reactions were observed. However, 
hypotension, cardiac arrhythmias, and severe extravasation 
injuries are well recognised adverse effects of phenytoin; 
rarely, the cardiovascular effects might be fatal.12–14 
Levetiracetam was well tolerated when admin istered over 
5 min, a more rapid rate than previously reported.16,17,27 
Agitation was the most common adverse event in the 
levetiracetam group, as reported previously.15 There were 
no new or unexpected serious adverse reactions with 
levetiracetam. Sedation, somnolence, and dizziness are 
rare side-effects of levetiracetam in adults, but these rare 
side-effects might in part be due to use of benzodiazepines 
or craniotomy in the study popu lation.18,28 Anxiety has also 
been reported in adults but was not reported as an adverse 
event or reaction in this or other paediatric studies. 
However, anxiety might be similar to the agitation that 
was seen and reported in EcLiPSE. Because 90% of our 
study population was  younger than 10 years (and 41% 
aged 2 years or under),  anxiety might be difficult, if not 
impossible, for them or their carers to descibe, instead 
using the terms agitated or irritable.
The EcLiPSE trial is unique for many reasons. To our 
knowledge, it is the first adequately powered randomised 
clinical trial to compare the efficacy and safety of two 
anticonvulsants for second-line treatment of convulsive 
status epilepticus. Second, it is an adequately powered 
randomised clinical trial to evaluate phenytoin as a 
second-line treatment for convulsive status epilepticus, 
despite this drug being used as the first-choice second-
line treatment for more than 50 years. Third, we 
incorporated a nested consent study that evaluated the 
process of research without prior consent in a paediatric 
emergency medicine trial.22–24 Finally, this was the 
first multicentre randomised clinical trial to be supported 
by, and delivered across, the PERUKI collaborative.20
This trial has several strengths. First, it evaluated a 
specific step (second-line treatment) in a commonly used 
UK clinical algorithm for the management of paediatric 
convulsive status epilepticus.7 A similar trial assessing 
the first-line, non-intravenous treatment of convulsive 
status epilepticus in the same algorithm led to a change 
in national clinical practice.29 Second, this trial showed 
that research without prior consent is acceptable and 
successful, with 385 (95%) of 404 ran domised participants 
providing consent; in those who were randomised and 
treated, 286 (92%) of 311 provided consent. Research 
without prior consent is essential for the successful 
delivery of trials in paediatric emergency care. The high 
consent rate mirrors that found in a previous trial of first-
line management of convulsive status epilepticus 
(consent rate 97%),29 and in a pilot randomised clinical 
trial that compared fluid boluses in shock (consent rate 
100%).30 Third, this was a pragmatic trial, and recorded 
only key primary and secondary outcomes in the 
resuscitation room. This approach, supported by focused 
data-collection materials and simple allocation and 
enrolment methods, facilitated successful delivery of the 
study across all sites, as shown by low numbers of missed 
patients, high protocol adherence, and accurate data 
capture for key outcomes. Finally, the trial was conducted 
in emergency depart ments from secondary and tertiary 
care centres throughout PERUKI, increasing the 
generalisability of our findings, and facilitating rapid 
dissemination and knowledge translation.
This trial has some limitations. First, it was open-label. 
A double-blind design was considered too complex for 
most participating sites (partly because of the substantially 
different infusion rates of the two drugs) and in the 
context of the life-threatening nature of convulsive status 
epilepticus. Second, assessment of cessation of all signs 
of continuous, rhythmic clonic activity (rather using than 
fixed timepoints to assess cessation of convulsive status 
epilepticus) was probably subjective. Clearly, these two 
limitations might collectively increase the risk of bias. 
However, continual assessment of a child’s condition 
reflects real-life clinical practice in a dynamic situation, in 
which clinicians constantly evaluate and prepare for 
the next step in the treatment algorithm. Site training 
included a simulated demonstration of the endpoint to 
ensure an understanding of the key outcome measure for 
the trial. It would not have been feasible or pragmatic for 
each participant to undergo a video recording or an 
electroencephalogram (EEG) to determine the time of 
convulsive status epilepticus cessation more precisely. 
Without EEGs, it is not possible to state definitively 
whether any patients developed non-convulsive status 
epilepticus. However, treatment algorithms for non-
convulsive status epilepticus would follow the same flow 
as for convulsive status epilepticus, and there was no 
difference between treatment groups in the number of 
additional anticonvulsants given after trial treatment. 
Third, the timing of randomisation meant that convulsive 
status epilepticus terminated before administration of 
trial treatment in many cases; however, this affected both 
treatment groups equally, and was essential to maintain 
high standards of clinical care and to avoid treatment 
delays. Finally, we included safety measures as key 
secondary outcomes because of previous reports of harm. 
However, this trial was not powered to show a difference 
in the number of serious adverse reactions (a secondary 
outcome) between treatment groups.
Other treatment-related factors might be relevant to 
the interpretation of our findings. These include the 
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widespread use of levetiracetam as maintenance 
therapy for many childhood epilepsies because of its 
broad-spectrum activity and safety profile. In the EcLiPSE 
trial participants, levetiracetam was the most commonly 
used oral antiepilepsy drug at the time of presentation. 
Anecdotally, clinicians are reluctant to give a loading dose 
of phenytoin to children in convulsive status epilepticus 
who are on oral maintenance phenytoin because of 
potential cardiovascular toxicity. There seemed to be no 
similar concerns for levetiracetam, and no increase in 
adverse events was observed when giving 40 mg/kg to 
children already receiving maintenance levetiracetam. A 
substantial minority of children who present in convulsive 
status epilepticus for the first time are subsequently 
commenced on maintenance therapy. Levetiracetam is 
more likely than phenytoin to be used as maintenance 
therapy because of phenytoin’s adverse event profile and 
complex pharmacokinetics. One observational study in 
adults showed that 8% of patients treated with intravenous 
fosphenytoin for convulsive status epilepticus were 
subsequently commenced on oral phenytoin, whereas 
78% of those treated with intravenous levetiracetam were 
subsequently commenced on oral levetiracetam.26 Ease of 
drug preparation and administration is also a factor in the 
management of convulsive status epilepticus. Throughout 
the EcLiPSE trial, levetiracetam was reported by clinical 
teams in the participating centres to be easier to prepare 
and administer than phenytoin because of the calculations 
performed in reconstituting phenytoin, the number of 
vials required, and procedures needed for its admin-
istration; these observations are supported by the 
scientific literature.14,18,28
Strategies for management of convulsive status 
epilepticus are evolving. This includes the increasing use 
of two or more second-line treatments before progression 
to RSI, in preference to the traditional practice of 
immediate progression to RSI after failure of a single 
second-line treatment. 24 participants in the EcLiPSE trial 
received both second-line treatments sequentially. Of 
whom, 17 were randomly assigned to and received 
levetiracetam first. This could reflect an acceptability issue 
of a second second-line treatment being conditional on the 
amount of time lapsed. Clinicians might consider the risks 
of RSI to be greater than the risks of administration and 
assessment of an additional second-line treatment. 
However, the administration of two second-line treat ments 
might substantially delay the use of RSI, which could be 
detrimental to the child and contribute to neurological and 
cognitive impairment. The shorter administration time of 
levetiracetam (by contrast with 20 min or more for 
phenytoin) could make it an appealing first-choice second-
line treatment. Finally, intravenous levetiracetam has been 
shown to be as effective (76%) as intravenous lorazepam 
(the current first-choice first-line treatment for convulsive 
status epilepticus) in terminating convulsive status 
epilepticus in adults,27 which might justify further study.
The EcLiPSE trial did not show that levetiracetam was 
superior to phenytoin in cessation rate of convulsive 
status epilepticus, the time taken to terminate convulsive 
status epilepticus, or adverse reactions and events. 
However, the results, together with previously reported 
safety profiles and relative ease of administration of 
levetiracetam, suggest that it could be an appropriate 
alternative to phenytoin as the first-choice anticonvulsant 
for second-line treatment of paediatric convulsive status 
epilepticus.
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